scholarly journals Towards Understanding Mechanisms of Drug Action and Functions of the Body on the Molecular Level. New strategy on medical research after completion of genome sequencing.

2001 ◽  
Vol 118 (3) ◽  
pp. 170-176 ◽  
Author(s):  
Koichi ISHIKAWA ◽  
Gozoh TSUJIMOTO
1990 ◽  
Vol 78 (1) ◽  
pp. 1-1
Author(s):  
M. J. Brown

From this issue, Clinical Science will increase its page numbers from an average of 112 to 128 per monthly issue. This welcome change — equivalent to at least two manuscripts — has been ‘forced’ on us by the increasing pressure on space; this has led to an undesirable increase in the delay between acceptance and publication, and to a fall in the proportion of submitted manuscripts we have been able to accept. The change in page numbers will instead permit us now to return to our exceptionally short interval between acceptance and publication of 3–4 months; and at the same time we shall be able not only to accept (as now) those papers requiring little or no revision, but also to offer hope to some of those papers which have raised our interest but come to grief in review because of a major but remediable problem. Our view, doubtless unoriginal, has been that the review process, which is unusually thorough for Clinical Science, involving a specialist editor and two external referees, is most constructive when it helps the evolution of a good paper from an interesting piece of research. Traditionally, the papers in Clinical Science have represented some areas of research more than others. However, this has reflected entirely the pattern of papers submitted to us, rather than any selective interest of the Editorial Board, which numbers up to 35 scientists covering most areas of medical research. Arguably, after the explosion during the last decade of specialist journals, the general journal can look forward to a renaissance in the 1990s, as scientists in apparently different specialities discover that they are interested in the same substances, asking similar questions and developing techniques of mutual benefit to answer these questions. This situation arises from the trend, even among clinical scientists, to recognize the power of research based at the cellular and molecular level to achieve real progress, and at this level the concept of organ-based specialism breaks down. It is perhaps ironic that this journal, for a short while at the end of the 1970s, adopted — and then discarded — the name of Clinical Science and Molecular Medicine, since this title perfectly represents the direction in which clinical science, and therefore Clinical Science, is now progressing.


2010 ◽  
Vol 17 (4) ◽  
pp. 379-391
Author(s):  
Petra Jonvallen

This article examines how sex differentiation is invoked from body fat with a focus on how various monitoring devices participate in the construction of bodies. By using the concept of ‘local biologies’, denoting the linkage of the body to place with its local physical and social conditions, it argues against the ‘one-size-fits-all’ paradigm of modern medicine and critiques the mechanistic search for regularity in medical research. By looking at medical literature on obesity and how contemporary obesity researchers and clinicians link body fat to sex, local biologies of bodies in a Swedish obesity clinic are contrasted to the universal biologies represented in medical research. The article also provides empirical examples of how fat has the potential to undermine traditional sex and gender binaries.


2020 ◽  
Vol 12 (19) ◽  
pp. 8055
Author(s):  
Vasco Santos ◽  
Paulo Ramos ◽  
Nuno Almeida ◽  
Enrique Santos-Pavón

This study develops a scale to measure wine tourism experiences and was tested in Portugal, in two of the main wine tourism centres: Porto and Madeira. The wine experience scale combines experience traits with the traditional approach to scales related to wine tourism. The development of the scale follows the most recognised validated procedures. Data were collected from a total of 647 international wine tourists in the wine cellars of the two main fortified wine tourism regions visiting areas: Porto and Madeira. Structural equation modelling (SEM-AMOS) was used as the main analysis and validation tool. The resulting 18-item wine experience scale comprises four major dimensions: (1) Wine storytelling, (2) wine tasting excitement, (3) wine involvement, and (4) winescape. All these showed reliable and validated indicators. This new scale presents a valid new tool to better measure and evaluate experiences in a wine tourism setting. This study offers a broad range of use for academics, managers, planners, and practitioners. It shows how a new measurement tool focused on the wine tourism experience in terms of several outcomes and applications, addressing important practical managerial implications, can have an impact on academic research. Most previous tourism scales still fail to measure the specifics of wine settings. This is the first scale that comprises the dimensions of experience with wine senses, applied in a relevant wine destination where research is still limited. The results are relevant in boosting the increasingly recognized awareness of Portugal as wine tourism, as well as bringing experience scales to the body of knowledge.


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 7062-7062
Author(s):  
Min Yuan ◽  
Qian Ziliang ◽  
Juemin Fang ◽  
Zhongzheng Zhu ◽  
Jianguo Wu ◽  
...  

7062 Background: Cancer is a group of genetic diseases that result from changes in the genome of cells in the body, leading them to grow uncontrollably. Recent researches suggest Chromosome instability (CIN), which is defined as an increased rate of chromosome gains and losses, manifests as cell-to-cell karyotypic heterogeneity and drives cancer initiation and evolution. Methods: In the past two years, we initiated iStopCancer project, and characterized 4515 ‘best available’ minimal-invasive samples from cancer patients and 1501 plasma samples from non-tumor diseases by using low-pass whole genome sequencing. DNA from ‘best available’ minimal-invasive samples, including peripheral plasma, urines, pancreatic juice, bile and effusions were analyzed by low coverage whole genome sequencing followed by the UCAD Bioinformatics workflow to characterize the CINs. In total, 32T bp nucleotide (coverage =1.7X for each sample) were collected. All the data can be visualized on website: http://www.istopcancer.net/pgweb/cn/istopcancer.jsp . Results: 3748(83%) of tumors present detectable CIN (CIN score>1000) in minimal-invasive samples. The missed cancer patients were majorly from patients with either tumor size less than 2cm or less-aggressive cancers, including thyroid cancer, low-grade urothelial carcinoma, lung cancer in-situ, et al. Of the 1501 non-tumor individuals, 30(2.0%) present detectable CIN (|Z|>=3) at the time of sample collection, 24(80.0%) was diagnosed as tumor patient in 3-6 months follow-up. There were 9 (0.59%) of non-cancer individuals without detectable CIN were also reported as tumor patients during 6-month following up. In summary, the positive and negative prediction value is 80.0% and 99.4% respectively. The false alarms were majorly from patients with EBV activations, which indicates virus may interference chromosome stability and drove virus-associated carcinogenesis. For the patient with repeated detections, plasma cfDNA CIN dynamics predicted clinical responses and disease recurrences. Quick clearance of plasma cfDNA CIN in 2-3 weeks was found in 153 (83.6%) patients. Meanwhile, no quick clearance was found in majority of SDs/PDs (73/88=83.0%). Furthermore, cfDNA CIN predicts clinical response 2-8 weeks ahead of traditional biomarkers (CEA, CA15-3, CA199, AFP et al). Conclusions: Large-scale low coverage whole genome sequencing data provides useful information for cancer detection and managements.


2013 ◽  
Vol 80 (1) ◽  
pp. 46-55 ◽  
Author(s):  
Matteo Bassi ◽  
Irene Santinello ◽  
Andrea Bevilacqua ◽  
Pierfrancesco Bassi

Nanotechnology is a multidisciplinary field originating from the interaction of several different disciplines, such as engineering, physics, biology and chemistry. New materials and devices effectively interact with the body at molecular level, yielding a brand new range of highly selective and targeted applications designed to maximize the therapeutic efficiency while reducing the side effects. Liposomes, quantum dots, carbon nanotubes and superparamagnetic nanoparticles are among the most assessed nanotechnologies. Meanwhile, other futuristic platforms are paving the way toward a new scientific paradigm, able to deeply change the research path in the medical science. The growth of nanotechnology, driven by the dramatic advances in science and technology, clearly creates new opportunities for the development of the medical science and disease treatment in human health care. Despite the concerns and the on-going studies about their safety, nanotechnology clearly emerges as holding the promise of delivering one of the greatest breakthroughs in the history of medical science.


Our successors in medical research will read, with amused tolerance, our frequent agonized protests that the volume of literature which we should comprehend exceeds our capacity. Those of us who teach and write text-books for medical students and practitioners are forced to depend more and more upon the review journals. The number and breadth of the fields in which one can pose, even transiently, as an authority are diminishing rapidly. But if one looked only at this aspect of the picture an ageing outlook on the most fascinating of all games, medical research and teaching, might be suggested. The appearance of new authorities is most stimulating, and it is refreshingly obvious that the soaring rate of publication has not inhibited research. We must co-ordinate the abstracting services in our field, continue the struggle to eliminate unworthy papers, hope for even better colloquia and review journals, and confidently expect that the next fifty years will contribute more to medical science than has the past vigorous half-century. The award of the Croonian Lectureship has given me exceptional pleasure and a sense of great responsibility. In selecting a title I have considered the principal subjects in which I have endeavoured to keep abreast, and the choice has thus been narrowed to insulin and experimental diabetes, heparin and thrombosis, and the dietary factor choline and its precursors, which we have termed the lipotropic agents. Certain of the effects of these three substances might be discussed in a single lecture, since they all affect either the formation, distribution or the state of fat in the body. The action of a lipokinetic constituent of the anterior pituitary, first clearly demonstrated in our laboratory in 1936 (Best & Campbell), which increases the rate of mobilization of depot fat to the liver (Barrett, Best & Ridout 1938; Stetten & Salcedo 1944), might also have been included. The fat-mobilizing effect of anterior pituitary extracts may be due to Evans’s somatotropin, to the adrenocorticotropic hormone, to a more specific but as yet unidentified substance or, of course, to more than one of these. The four factors, insulin, choline, heparin and ‘adipokinin’ (Weil & Stetten 1947) have given us a measure of control over fat metabolism which our predecessors did not enjoy. There are, of course, other dietary and hormonal agents affecting these processes which one would have to discuss in a comprehensive treatment of the field. I shall not even list these and, indeed, after a very brief consideration of insulin and heparin, particularly in relation to fat metabolism, I shall limit my discussion to ‘the lipotropic agents’.


FEBS Letters ◽  
1978 ◽  
Vol 91 (2) ◽  
pp. 374-375
Author(s):  
E. Cundliffe ◽  
J.R. Thompson
Keyword(s):  

2021 ◽  
Vol 16 (11) ◽  
pp. 1934578X2110609
Author(s):  
Xiaofan Guo ◽  
Shouming Wang

Inonotus obliquus is a rare, edible and medicinal fungus that is widely used as a remedy for various diseases. Its main bioactive substances are polysaccharides and terpenoids. In this study, we characterized and investigated the pan-genome of three strains of I. obliquus. The genome sizes of JL01, HE, and NBRC8681 were 32.04, 29.04, and 31.78 Mb, respectively. There were 6 543 core gene families and 6 197 accessory gene families among the three strains, with 14 polysaccharide-related core gene families and seven accessory gene families. For terpenoids, there were 13 core gene families and 17 accessory gene families. Pan-genome sequencing of I. obliquus has improved our understanding of biological characteristics related to the biosynthesis of polysaccharides and terpenoids at the molecular level, which in turn will enable us to increase the production of polysaccharides and terpenoids by this mushroom.


Sign in / Sign up

Export Citation Format

Share Document